Please use this identifier to cite or link to this item:
|Title:||Mcl-1 and Bcl-xLsequestration of Bak confers differential resistance to BH3-only proteins.|
|Authors:||Hockings, Colin;Alsop, Amber E;Fennell, Stephanie C;Lee, Erinna F;Fairlie, W Douglas;Dewson, Grant;Kluck, Ruth M|
|Affiliation:||The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, 3052, Australia..|
Department of Medical Biology, The University of Melbourne, Parkville, VIC, 3010, Australia
Department of Chemical Engineering and Biotechnology, Cambridge, CB3 0AS, UK
Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia
School of Cancer Medicine, La Trobe University, Melbourne, VIC, 3086, Australia
Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, Melbourne, VIC, 3086, Australia
|Citation:||Cell death and differentiation 2018; online first: 19 February|
|Abstract:||The prosurvival Bcl-2 family proteins Mcl-1 and Bcl-xLinhibit apoptosis by sequestering BH3-only proteins such as Bid and Bim (MODE 1) or the effector proteins Bak and Bax (MODE 2). To better understand the contributions of MODE 1 and MODE 2 in blocking cell death, and thus how to bypass resistance to cell death, we examined prescribed mixtures of Bcl-2 family proteins. In a Bim and Bak mixture, Bcl-xLand Mcl-1 each sequestered not only Bim but also Bak as it became activated by Bim. In contrast, in a Bid and Bak mixture, Bcl-xLpreferentially sequestered Bid while Mcl-1 preferentially sequestered Bak. Notably, Bcl-xLcould sequester Bak in response to the BH3 mimetic ABT-737, despite this molecule targeting Bcl-xL. These findings highlight the importance of Bak sequestration in resistance to anti-cancer treatments, including BH3 mimetics.|
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.